Sulfinpyrazone
Systematic (IUPAC) name | |
---|---|
1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione | |
Clinical data | |
Trade names | Apo-sulfinpyrazone |
AHFS/Drugs.com | monograph |
MedlinePlus | a682339 |
Routes of administration | oral intravenous |
Pharmacokinetic data | |
Protein binding | 98–99% |
Metabolism | hepatic |
Excretion | renal |
Identifiers | |
CAS Number | 57-96-5 |
ATC code | M04AB02 (WHO) |
PubChem | CID 5342 |
IUPHAR/BPS | 5826 |
DrugBank | DB01138 |
ChemSpider | 5149 |
UNII | V6OFU47K3W |
KEGG | D00449 |
ChEBI | CHEBI:9342 |
ChEMBL | CHEMBL832 |
Chemical data | |
Formula | C23H20N2O3S |
Molar mass | 404.48 g/mol |
| |
| |
(verify) |
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.
Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.
Contraindications
Sulfinpyrazone must not be used in persons with renal impairment or a high rate of excretion of uric acid (hyperuricosuria).[1]
References
- ↑ Underwood M (June 2006). "Diagnosis and management of gout". BMJ 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.
|
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.